Zhihua Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zhihua Huang has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Zhihong Liu
Center for Respiratory and Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
6 shared publications - Qin Luo
Center for Respiratory and Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications Anqi Duan
Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , No. 167, Beilishi Road, Xicheng District, Beijing 100037
4 shared publicationsChenhong An
Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , No. 167, Beilishi Road, Xicheng District, Beijing 100037
4 shared publicationsLuyang Gao
Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , No. 167, Beilishi Road, Xicheng District, Beijing 100037
4 shared publicationsXin Li
Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College , No. 167, Beilishi Road, Xicheng District, Beijing 100037
4 shared publications
Latest Publications
- 16 October 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Event-weighted desaturation burden and cardiovascular mortality in sleep apnoea: findings from a large community-based prospective cohort
Aims: Obstructive sleep apnoea’s prognostic value is limited by reliance on the apnoea–hypopnoea index (AHI), which fails to capture the physiological heterogeneity of respiratory events. We developed a composite metric, event-weighted desaturation burden (EWDB), integrating weighted respiratory event load, regularity of consecutive inter-event intervals, and cumulative desaturation area. We evaluated its association with cardiovascular mortality and its incremental prognostic value compared with AHI and established hypoxic metrics. Methods and results: We analysed 4904 adults from the Sleep Heart Health Study with baseline polysomnography and adjudicated follow-up. EWDB was derived by combining a Respiratory Weighted Index, a distribution factor based on inter-event interval regularity, and event-linked hypoxic burden (HB). The primary outcome was cardiovascular mortality. Over a median follow-up of approximately 11 years, 341 cardiovascular deaths occurred. In fully adjusted multivariable Cox models, higher EWDB was independently associated with cardiovascular mortality. However, AHI and HB associations were attenuated and lost statistical significance after full adjustment. EWDB (per 1 SD increase) remained robustly associated with cardiovascular mortality, whereas AHI did not. Incorporating EWDB into a comprehensive clinical model provided incremental risk stratification. Similar robust associations were observed for fatal coronary heart disease and incident heart failure. Conclusion: EWDB was independently associated with cardiovascular mortality and provided incremental prognostic information beyond established clinical and sleep-related factors in this cohort. By integrating respiratory event intensity, cumulative burden, and inter-event interval regularity, EWDB may better characterize cardiovascular stress related to sleep-disordered breathing.
- 16 October 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Event-weighted desaturation burden and cardiovascular mortality in sleep apnoea: findings from a large community-based prospective cohort
Aims: Obstructive sleep apnoea’s prognostic value is limited by reliance on the apnoea–hypopnoea index (AHI), which fails to capture the physiological heterogeneity of respiratory events. We developed a composite metric, event-weighted desaturation burden (EWDB), integrating weighted respiratory event load, regularity of consecutive inter-event intervals, and cumulative desaturation area. We evaluated its association with cardiovascular mortality and its incremental prognostic value compared with AHI and established hypoxic metrics. Methods and results: We analysed 4904 adults from the Sleep Heart Health Study with baseline polysomnography and adjudicated follow-up. EWDB was derived by combining a Respiratory Weighted Index, a distribution factor based on inter-event interval regularity, and event-linked hypoxic burden (HB). The primary outcome was cardiovascular mortality. Over a median follow-up of approximately 11 years, 341 cardiovascular deaths occurred. In fully adjusted multivariable Cox models, higher EWDB was independently associated with cardiovascular mortality. However, AHI and HB associations were attenuated and lost statistical significance after full adjustment. EWDB (per 1 SD increase) remained robustly associated with cardiovascular mortality, whereas AHI did not. Incorporating EWDB into a comprehensive clinical model provided incremental risk stratification. Similar robust associations were observed for fatal coronary heart disease and incident heart failure. Conclusion: EWDB was independently associated with cardiovascular mortality and provided incremental prognostic information beyond established clinical and sleep-related factors in this cohort. By integrating respiratory event intensity, cumulative burden, and inter-event interval regularity, EWDB may better characterize cardiovascular stress related to sleep-disordered breathing.
- Open Access
- 28 July 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (7)
Cardiovascular Disease, Sleep-Disordered Breathing, and Artificial Intelligence: From Neutral Trials to Precision Sleep Cardiology
Sleep-disordered breathing (SDB), which includes both obstructive and central sleep apnea, is highly prevalent among patients with cardiovascular disease (CVD). Moreover, SDB contributes significantly to the development and progression of hypertension, coronary artery disease, arrhythmias, heart failure, and various cardiovascular and cerebrovascular events. However, despite strong mechanistic links involving intermittent hypoxemia, sympathetic activation, intrathoracic pressure fluctuations, and systemic inflammation, clinical trials of SDB treatment have yielded in neutral or even adverse cardiovascular outcomes. These results underscore the need for refined phenotyping, risk stratification, and personalized management. Artificial intelligence (AI) has emerged as a promising tool to address these challenges. In this review, we evaluate the mechanistic pathways through which SDB affects cardiovascular health and critically examine AI-based methods to enhance screening, outcome prediction, and treatment optimization. Applications include automated detection using clinical and biosignal data, cardiovascular risk prediction through machine-learning models based on sleep parameters, and AI-guided therapy personalization. Furthermore, we emphasize translational relevance by comparing model performance, identifying high-risk phenotypes, and exploring the potential for integration into clinical workflows. AI-enabled tools may help bridge the gap between pathophysiological understanding and improved outcomes by facilitating earlier diagnosis, tailored interventions, and proactive monitoring. Future studies should focus on prospective validation, regulatory pathways, and equitable deployment across populations.
- 28 July 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (7)
Open AccessCardiovascular Disease, Sleep-Disordered Breathing, and Artificial Intelligence: From Neutral Trials to Precision Sleep Cardiology
Sleep-disordered breathing (SDB), which includes both obstructive and central sleep apnea, is highly prevalent among patients with cardiovascular disease (CVD). Moreover, SDB contributes significantly to the development and progression of hypertension, coronary artery disease, arrhythmias, heart failure, and various cardiovascular and cerebrovascular events. However, despite strong mechanistic links involving intermittent hypoxemia, sympathetic activation, intrathoracic pressure fluctuations, and systemic inflammation, clinical trials of SDB treatment have yielded in neutral or even adverse cardiovascular outcomes. These results underscore the need for refined phenotyping, risk stratification, and personalized management. Artificial intelligence (AI) has emerged as a promising tool to address these challenges. In this review, we evaluate the mechanistic pathways through which SDB affects cardiovascular health and critically examine AI-based methods to enhance screening, outcome prediction, and treatment optimization. Applications include automated detection using clinical and biosignal data, cardiovascular risk prediction through machine-learning models based on sleep parameters, and AI-guided therapy personalization. Furthermore, we emphasize translational relevance by comparing model performance, identifying high-risk phenotypes, and exploring the potential for integration into clinical workflows. AI-enabled tools may help bridge the gap between pathophysiological understanding and improved outcomes by facilitating earlier diagnosis, tailored interventions, and proactive monitoring. Future studies should focus on prospective validation, regulatory pathways, and equitable deployment across populations.
- Open Access
- 2 December 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (12) , e70426
Impact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension
Prognostic assessment of chronic thromboembolic pulmonary hypertension (CTEPH) remains challenging. Stress hyperglycemia, a condition where glucose metabolism is regulated during stress, has been regarded as an indicator of acute hyperglycemia. The stress hyperglycemia ratio (SHR) serves as a more precise marker for this state. This research intended to investigate the prognostic function of SHR in CTEPH, as its link to poor outcomes is uncertain. Clinical deterioration events were the primary endpoint. LASSO regression was utilized for variable selection and dimensionality reduction to identify key features and mitigate overfitting. Kaplan–Meier analysis, multivariable Cox regression, and restricted cubic splines were primarily used to investigate the link between SHR and adverse clinical outcomes. Internal validation was performed using bootstrap resampling. Sensitivity analysis was performed to assess the robustness of the findings. The study included a sum of 451 patients with CTEPH; over a median follow‐up of 21 months, 89 (19.7%) patients encountered adverse outcomes. Kaplan–Meier analysis indicated that patients having elevated SHR levels exhibited a markedly higher overall incidence of adverse events. Restricted cubic spline analysis showed a linear relationship between SHR and adverse events. Multivariable Cox regression analysis indicated that higher SHR independently predicts adverse outcomes, whether treated as continuous (hazard ratio, 1.541; 95% confidence interval, 1.252–1.896, p < 0.001) or categorical (hazard ratio, 2.419; 95% confidence interval, 1.268–4.616, p = 0.007). Internal validation demonstrated that the original C‐index was 0.693, with a bias‐corrected C‐index of 0.675 after bootstrap validation. In patients with CTEPH, higher SHR is independently associated with clinical worsening. The prognostic significance of SHR remained robust across internal validation and multiple sensitivity analyses.
- 2 December 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (12) , e70426
Open AccessImpact of Stress Hyperglycemia Ratio on Adverse Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension
Prognostic assessment of chronic thromboembolic pulmonary hypertension (CTEPH) remains challenging. Stress hyperglycemia, a condition where glucose metabolism is regulated during stress, has been regarded as an indicator of acute hyperglycemia. The stress hyperglycemia ratio (SHR) serves as a more precise marker for this state. This research intended to investigate the prognostic function of SHR in CTEPH, as its link to poor outcomes is uncertain. Clinical deterioration events were the primary endpoint. LASSO regression was utilized for variable selection and dimensionality reduction to identify key features and mitigate overfitting. Kaplan–Meier analysis, multivariable Cox regression, and restricted cubic splines were primarily used to investigate the link between SHR and adverse clinical outcomes. Internal validation was performed using bootstrap resampling. Sensitivity analysis was performed to assess the robustness of the findings. The study included a sum of 451 patients with CTEPH; over a median follow‐up of 21 months, 89 (19.7%) patients encountered adverse outcomes. Kaplan–Meier analysis indicated that patients having elevated SHR levels exhibited a markedly higher overall incidence of adverse events. Restricted cubic spline analysis showed a linear relationship between SHR and adverse events. Multivariable Cox regression analysis indicated that higher SHR independently predicts adverse outcomes, whether treated as continuous (hazard ratio, 1.541; 95% confidence interval, 1.252–1.896, p < 0.001) or categorical (hazard ratio, 2.419; 95% confidence interval, 1.268–4.616, p = 0.007). Internal validation demonstrated that the original C‐index was 0.693, with a bias‐corrected C‐index of 0.675 after bootstrap validation. In patients with CTEPH, higher SHR is independently associated with clinical worsening. The prognostic significance of SHR remained robust across internal validation and multiple sensitivity analyses.
- Open Access
- 1 January 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 447-460
Role of the Systemic Inflammatory Response Index in Predicting Disease Severity and Prognosis in Idiopathic Pulmonary Arterial Hypertension
Introduction: Mounting evidence indicates a possible connection between the systemic inflammatory response index (SIRI) and the prognosis of heart failure, but its role in idiopathic pulmonary arterial hypertension (IPAH) is not well understood. This study aimed to investigate the relationship between SIRI and variables such as functional ability, echocardiography results, hemodynamic measurements, and long-term outcomes in patients with IPAH. Methods: The study included 426 consecutive IPAH patients who underwent right heart catheterization at Fuwai Hospital from January 2013 to December 2020. SIRI was calculated using composite inflammation indicators from routine blood tests. The main outcome measure was clinical deterioration. Spearman correlation coefficients were used to assess associations between SIRI and indicators of IPAH severity. Receiver operating characteristic (ROC) curve analysis was conducted to determine the optimal SIRI threshold and predictive ability. Kaplan-Meier analysis and Cox proportional hazard models were used to examine the relationship between SIRI and clinical deterioration. Results: SIRI showed positive associations with indicators such as N-terminal pro-brain natriuretic peptide, right ventricular end-diastolic diameter, pericardial effusion, mean pulmonary arterial pressure, and pulmonary vascular resistance. Conversely, SIRI had inverse relationships with 6-minute walking distance and left ventricular end-diastolic diameter. Kaplan-Meier curves revealed a significantly higher rate of clinical deterioration in individuals with SIRI > 0.741 compared to those with SIRI ≤ 0.741 (P < 0.001). Adjusted Cox analysis showed SIRI remained an independent predictor of clinical worsening (hazard ratio 1.366, 95% confidence interval 1.073– 1.738, P = 0.011). ROC analysis demonstrated SIRI provided additional predictive value beyond the risk assessment score of the European Society of Cardiology/European Respiratory Society. Discussion: In summary, SIRI could predict the severity and prognosis of IPAH independently. It was associated with various indicators of IPAH severity and was a significant predictor of clinical deterioration. SIRI also offered additional predictive value beyond existing risk assessment scores.
- 1 January 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 447-460
Open AccessRole of the Systemic Inflammatory Response Index in Predicting Disease Severity and Prognosis in Idiopathic Pulmonary Arterial Hypertension
Introduction: Mounting evidence indicates a possible connection between the systemic inflammatory response index (SIRI) and the prognosis of heart failure, but its role in idiopathic pulmonary arterial hypertension (IPAH) is not well understood. This study aimed to investigate the relationship between SIRI and variables such as functional ability, echocardiography results, hemodynamic measurements, and long-term outcomes in patients with IPAH. Methods: The study included 426 consecutive IPAH patients who underwent right heart catheterization at Fuwai Hospital from January 2013 to December 2020. SIRI was calculated using composite inflammation indicators from routine blood tests. The main outcome measure was clinical deterioration. Spearman correlation coefficients were used to assess associations between SIRI and indicators of IPAH severity. Receiver operating characteristic (ROC) curve analysis was conducted to determine the optimal SIRI threshold and predictive ability. Kaplan-Meier analysis and Cox proportional hazard models were used to examine the relationship between SIRI and clinical deterioration. Results: SIRI showed positive associations with indicators such as N-terminal pro-brain natriuretic peptide, right ventricular end-diastolic diameter, pericardial effusion, mean pulmonary arterial pressure, and pulmonary vascular resistance. Conversely, SIRI had inverse relationships with 6-minute walking distance and left ventricular end-diastolic diameter. Kaplan-Meier curves revealed a significantly higher rate of clinical deterioration in individuals with SIRI > 0.741 compared to those with SIRI ≤ 0.741 (P < 0.001). Adjusted Cox analysis showed SIRI remained an independent predictor of clinical worsening (hazard ratio 1.366, 95% confidence interval 1.073– 1.738, P = 0.011). ROC analysis demonstrated SIRI provided additional predictive value beyond the risk assessment score of the European Society of Cardiology/European Respiratory Society. Discussion: In summary, SIRI could predict the severity and prognosis of IPAH independently. It was associated with various indicators of IPAH severity and was a significant predictor of clinical deterioration. SIRI also offered additional predictive value beyond existing risk assessment scores.
- Open Access
- 1 September 2023
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 15, 705-717
Impact of Obstructive Sleep Apnea on Disease Severity and Adverse Outcomes in Patients with Acute Pulmonary Embolism
Purpose: Acute pulmonary embolism (PE) poses a life-threatening risk with high mortality rates. While the coexistence of PE and obstructive sleep apnea (OSA) is gaining recognition, its influence on PE severity and prognosis remains uncertain. This study aims to investigate the associations between OSA and disease severity, as well as outcomes, in patients with acute PE. Patients and Methods: We conducted a retrospective cohort study on patients diagnosed with acute PE who had undergone previous cardiorespiratory polygraphy. OSA severity was assessed using the apnea-hypopnea index (AHI) derived from cardiorespiratory polygraphy. The severity of acute PE was evaluated using the simplified Pulmonary Embolism Severity Index (sPESI) score. Logistic regression analysis was performed to investigate the associations between AHI and the risk of belonging to the sPESI≥ 1 group. Cox regression analysis was used to examine the relationship between AHI and long-term adverse events, defined as a composite of all-cause mortality and non-fatal cardiovascular events. Results: Among 145 acute PE patients (mean age 62.2 years, 49.7% male), 94 (64.8%) had OSA. Patients with OSA had a significantly higher proportion of sPESI≥ 1 (89.4% vs 68.6%, p=0.002) than non-OSA patients. Each unit increase in AHI was associated with a 15% increased risk of severe PE (sPESI≥ 1) (odds ratio: 1.15, 95% CI 1.05– 1.26, p=0.002) after adjusting for confounders. During a median follow-up of 15.2 months, 27 (18.6%) patients experienced adverse events. Increased AHI independently predicted a higher risk of adverse events (hazard ratio: 1.03, 95% CI: 1.00– 1.05, p=0.026), even after adjusting for potential confounders. AHI ≥ 8 events/h was associated with a significantly higher adjusted hazard ratio of 2.56 (95% CI: 1.15– 5.72, p=0.022) for adverse events compared to AHI < 8 events. Conclusion: OSA is common in acute PE patients and is linked to increased disease severity and adverse outcomes. Implementing routine OSA screening and management may aid risk stratification and improve outcomes in acute PE patients.
- 1 September 2023
- Published by Taylor & Francis in Nature and Science of Sleep
- Vol. ume 15, 705-717
Open AccessImpact of Obstructive Sleep Apnea on Disease Severity and Adverse Outcomes in Patients with Acute Pulmonary Embolism
Purpose: Acute pulmonary embolism (PE) poses a life-threatening risk with high mortality rates. While the coexistence of PE and obstructive sleep apnea (OSA) is gaining recognition, its influence on PE severity and prognosis remains uncertain. This study aims to investigate the associations between OSA and disease severity, as well as outcomes, in patients with acute PE. Patients and Methods: We conducted a retrospective cohort study on patients diagnosed with acute PE who had undergone previous cardiorespiratory polygraphy. OSA severity was assessed using the apnea-hypopnea index (AHI) derived from cardiorespiratory polygraphy. The severity of acute PE was evaluated using the simplified Pulmonary Embolism Severity Index (sPESI) score. Logistic regression analysis was performed to investigate the associations between AHI and the risk of belonging to the sPESI≥ 1 group. Cox regression analysis was used to examine the relationship between AHI and long-term adverse events, defined as a composite of all-cause mortality and non-fatal cardiovascular events. Results: Among 145 acute PE patients (mean age 62.2 years, 49.7% male), 94 (64.8%) had OSA. Patients with OSA had a significantly higher proportion of sPESI≥ 1 (89.4% vs 68.6%, p=0.002) than non-OSA patients. Each unit increase in AHI was associated with a 15% increased risk of severe PE (sPESI≥ 1) (odds ratio: 1.15, 95% CI 1.05– 1.26, p=0.002) after adjusting for confounders. During a median follow-up of 15.2 months, 27 (18.6%) patients experienced adverse events. Increased AHI independently predicted a higher risk of adverse events (hazard ratio: 1.03, 95% CI: 1.00– 1.05, p=0.026), even after adjusting for potential confounders. AHI ≥ 8 events/h was associated with a significantly higher adjusted hazard ratio of 2.56 (95% CI: 1.15– 5.72, p=0.022) for adverse events compared to AHI < 8 events. Conclusion: OSA is common in acute PE patients and is linked to increased disease severity and adverse outcomes. Implementing routine OSA screening and management may aid risk stratification and improve outcomes in acute PE patients.
- Open Access
- 26 August 2023
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-11
The potential of cystatin C as a predictive biomarker in pulmonary hypertension
Background: Cystatin C is a novel biomarker to identify renal dysfunction and cardiovascular risk. Objective: The aim of this study was to investigate the role of cystatin C in non-invasive risk prediction in a large cohort of patients with pre-capillary pulmonary hypertension (PH). Method: We retrospectively analyzed pre-capillary PH patients with available cystatin C and hemodynamic data derived from right heart catheterization. Results: A total of 398 consecutive patients with confirmed pre-capillary PH were recruited from Fuwai Hospital between November 2020 and November 2021. Over a median duration of 282 days, 72 (18.1%) of these patients experienced clinical worsening. Cystatin C levels significantly correlated with cardiac index (r = -0.286, P < 0.001), mixed venous oxygen saturation (r = -0.216, P < 0.001), and tricuspid annular plane systolic excursion (r = -0.236, P < 0.001), and high cystatin C levels independently predicted a poor prognosis after adjusting potential confounders in different models (all P < 0.05). A three-group non-invasive risk model was constructed based on the combined assessment of the cystatin C and WHO-FC using dichotomous cut-off value. Those patients with higher cystatin C (≥ 1.0 mg/L) and a worse WHO-FC experienced the highest risk of endpoint occurrence. The predictive capacity of this model was comparable to that of an existing invasive risk stratification model (area under curve: 0.657 vs 0.643, P = 0.619). Conclusions: Cystatin C levels were associated with disease severity and prognosis in patients with pre-capillary PH. A combination of high cystatin C and advanced WHO-FC identifies patients at particularly high risk of clinical deterioration.
- 26 August 2023
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-11
Open AccessThe potential of cystatin C as a predictive biomarker in pulmonary hypertension
Background: Cystatin C is a novel biomarker to identify renal dysfunction and cardiovascular risk. Objective: The aim of this study was to investigate the role of cystatin C in non-invasive risk prediction in a large cohort of patients with pre-capillary pulmonary hypertension (PH). Method: We retrospectively analyzed pre-capillary PH patients with available cystatin C and hemodynamic data derived from right heart catheterization. Results: A total of 398 consecutive patients with confirmed pre-capillary PH were recruited from Fuwai Hospital between November 2020 and November 2021. Over a median duration of 282 days, 72 (18.1%) of these patients experienced clinical worsening. Cystatin C levels significantly correlated with cardiac index (r = -0.286, P < 0.001), mixed venous oxygen saturation (r = -0.216, P < 0.001), and tricuspid annular plane systolic excursion (r = -0.236, P < 0.001), and high cystatin C levels independently predicted a poor prognosis after adjusting potential confounders in different models (all P < 0.05). A three-group non-invasive risk model was constructed based on the combined assessment of the cystatin C and WHO-FC using dichotomous cut-off value. Those patients with higher cystatin C (≥ 1.0 mg/L) and a worse WHO-FC experienced the highest risk of endpoint occurrence. The predictive capacity of this model was comparable to that of an existing invasive risk stratification model (area under curve: 0.657 vs 0.643, P = 0.619). Conclusions: Cystatin C levels were associated with disease severity and prognosis in patients with pre-capillary PH. A combination of high cystatin C and advanced WHO-FC identifies patients at particularly high risk of clinical deterioration.
- Open Access
- 21 December 2021
- Published by Spandidos Publications in Oncology Letters
- Vol. 23 (2) , 1-10
LINC01207 promotes prostate cancer progression by sponging miR‑1182 to upregulate AKT3
Prostate cancer (PC) is recognized as a common malignancy in male patients. Long non‑coding RNA (lncRNA) has been implicated in the development of PC. Recently, long intergenic non‑protein coding RNA 1207 (LINC01207) has been reported to regulate the carcinogenesis of multiple cancer types. However, its role in the progression of PC remains to be determined. The aim of the present study was to investigate the expression profile, clinicopathological implication and molecular mechanism of action of LINC01207 in the progression of PC. LINC01207 expression levels were compared between PC tumor and paired normal tissue samples from The Cancer Genome Atlas. The expression of LINC01207 was further analyzed in PC cell lines and a normal prostatic cell line. The role of LINC01207 in proliferation, migration and invasion of PC cells was examined using small interfering RNA‑mediated silencing. Western blot analysis was used to investigate the changes in protein levels underlying the mechanism of action of LINC01207. The role of LINC01207 in tumorigenesis was evaluated in a xenograft model. LINC01207 was upregulated in PC tumor samples from TCGA data compared with paired normal tissue. LINC01207 expression was significantly increased in PC cells and tumor tissues compared with in normal prostate cells (RWPE1) and normal prostate tissues, respectively. Furthermore, LINC01207 silencing inhibited PC cell proliferation and colony formation and induced apoptosis. Mechanistic experiments showed that LINC01207 promoted carcinogenesis by sponging miR‑1182 to regulate the protein levels of AKT3 in PC cell lines. Thus, the findings of the present study indicated that LINC01207 might play a role in the tumorigenesis of PC and may serve as a therapeutic target for PC treatment.
- 21 December 2021
- Published by Spandidos Publications in Oncology Letters
- Vol. 23 (2) , 1-10
Open AccessLINC01207 promotes prostate cancer progression by sponging miR‑1182 to upregulate AKT3
Prostate cancer (PC) is recognized as a common malignancy in male patients. Long non‑coding RNA (lncRNA) has been implicated in the development of PC. Recently, long intergenic non‑protein coding RNA 1207 (LINC01207) has been reported to regulate the carcinogenesis of multiple cancer types. However, its role in the progression of PC remains to be determined. The aim of the present study was to investigate the expression profile, clinicopathological implication and molecular mechanism of action of LINC01207 in the progression of PC. LINC01207 expression levels were compared between PC tumor and paired normal tissue samples from The Cancer Genome Atlas. The expression of LINC01207 was further analyzed in PC cell lines and a normal prostatic cell line. The role of LINC01207 in proliferation, migration and invasion of PC cells was examined using small interfering RNA‑mediated silencing. Western blot analysis was used to investigate the changes in protein levels underlying the mechanism of action of LINC01207. The role of LINC01207 in tumorigenesis was evaluated in a xenograft model. LINC01207 was upregulated in PC tumor samples from TCGA data compared with paired normal tissue. LINC01207 expression was significantly increased in PC cells and tumor tissues compared with in normal prostate cells (RWPE1) and normal prostate tissues, respectively. Furthermore, LINC01207 silencing inhibited PC cell proliferation and colony formation and induced apoptosis. Mechanistic experiments showed that LINC01207 promoted carcinogenesis by sponging miR‑1182 to regulate the protein levels of AKT3 in PC cell lines. Thus, the findings of the present study indicated that LINC01207 might play a role in the tumorigenesis of PC and may serve as a therapeutic target for PC treatment.
- 15 October 2020
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 16 (10) , 1675-1682
Impact of obstructive sleep apnea on left ventricular mass index in men with coronary artery disease
Study Objectives:Left ventricular hypertrophy (LVH) is associated with augmented risk for mortality in patients with coronary artery disease (CAD). These patients often have obstructive sleep apnea...
- 15 October 2020
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 16 (10) , 1675-1682
Impact of obstructive sleep apnea on left ventricular mass index in men with coronary artery disease
Study Objectives:Left ventricular hypertrophy (LVH) is associated with augmented risk for mortality in patients with coronary artery disease (CAD). These patients often have obstructive sleep apnea...
- Open Access
- 1 August 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 128, 110336
Comparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention
- 1 August 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 128, 110336
Open AccessComparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention
- 15 October 2019
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 15 (10) , 1403-1409
The Clinical Value of N-Terminal Pro B-Type Natriuretic Peptide in Evaluating Obstructive Sleep Apnea in Patients With Coronary Artery Disease
Study Objectives:Natriuretic peptides have been identified as biomarkers of increased myocardial wall stress in the context of obstructive sleep apnea (OSA) in the general population. However, the ...
- 15 October 2019
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 15 (10) , 1403-1409
The Clinical Value of N-Terminal Pro B-Type Natriuretic Peptide in Evaluating Obstructive Sleep Apnea in Patients With Coronary Artery Disease
Study Objectives:Natriuretic peptides have been identified as biomarkers of increased myocardial wall stress in the context of obstructive sleep apnea (OSA) in the general population. However, the ...